Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cortical cholinergic markers in schizophrenia

V Haroutunian1, M Davidson, P D Kanof

  • 1Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.

Schizophrenia Research
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blast-related disinhibition and risk seeking in mice and combat Veterans: Potential role for dysfunctional phasic dopamine release.

Neurobiology of disease·2017
Same author

Microprobe studies of aluminum accumulation in association with human central nervous system disease.

Environmental geochemistry and health·2013
Same author

Characterizing cognitive deficits and dementia in an aging urban population in India.

International journal of Alzheimer's disease·2012
Same author

Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles.

Current Alzheimer research·2011
Same author

Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons.

Neurology·2009
Same author

Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology.

Neurology·2008

Cognitive impairments in elderly schizophrenia patients are not linked to reduced cortical cholinergic activity. Unlike Alzheimer's disease patients, schizophrenic individuals showed normal levels of choline acetyltransferase and acetylcholinesterase.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Geriatric Psychiatry

Background:

  • Cortical cholinergic deficits are associated with cognitive impairment in neurodegenerative diseases like Alzheimer's disease (AD).
  • Cognitive deficits are frequently observed in chronically institutionalized geriatric schizophrenia patients.
  • The underlying cause of cognitive impairment in schizophrenia remains an area of investigation.

Purpose of the Study:

  • To compare cortical cholinergic marker activity between elderly controls, geriatric schizophrenia patients, and Alzheimer's disease patients.
  • To investigate the relationship between cholinergic activity and cognitive status in these cohorts.

Main Methods:

  • Postmortem analysis of six cortical regions.
  • Measurement of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity.

Related Experiment Videos

  • Neuropathological confirmation of Alzheimer's disease criteria.
  • Correlation analysis with Clinical Dementia Rating (CDR) scores.

    • Main Results:

    • Cholinergic marker activity (ChAT and AChE) was significantly reduced in Alzheimer's disease patients compared to controls.
    • No significant reduction in cortical cholinergic marker activity was observed in geriatric schizophrenia patients.
    • Cortical ChAT activity negatively correlated with CDR scores in the AD cohort, but not in the schizophrenia cohort.

    Conclusions:

    • Cognitive deficits in geriatric schizophrenia are unlikely to be caused by diminished cortical cholinergic activity.
    • Alzheimer's disease is characterized by significant cholinergic deficits, unlike schizophrenia in this cohort.
    • This study differentiates the neurochemical underpinnings of cognitive impairment in AD and schizophrenia.